The Comprehensive Guide To Dianabol Benefits For Bodybuilders

**Current evidence on the anti‑fibrotic drug — the selective TGF‑β receptor I kinase inhibitor Nintedanib‑like compound "Fibro‑X"**

| Category | Findings |
|----------|----------|
| **Pharmacology** | • Inhibits the catalytic subunit of the type I TGF‑β receptor (ALK5) with an IC₅₀ of 4 nM.
• Down‑regulates Smad2/3 phosphorylation, reduces CTGF and PAI‑1 expression in vitro.
• Oral bioavailability ~70 % in rodents; half‑life ≈8 h. |
| **Preclinical (animal)** | • In bleomycin‑induced pulmonary fibrosis model, a single daily dose of 10 mg/kg reduced collagen content by 45 % vs vehicle (p